“HGH” in casual usage means anything that pushes the GH axis up - secretagogue stack, recombinant injection, even oral pseudo-secretagogues like MK-677. Pharmacologically those aren’t interchangeable. Mod GRF 1-29 + Ipamorelin asks your own pituitary to pulse harder. Somatropin bypasses the pituitary and supplies recombinant GH directly. The signals look similar on a bloodwork sheet (IGF-1 goes up) but the kinetics, the ceiling, the side- effect surface, and the cost gap are different categories.
This article is the head-to-head for users deciding between “run a pulsatile GHRH+GHRP stack” and “run actual rhGH.” For the full per-compound playbook see GH Axis Playbook; for the pulsatile-vs-continuous architecture see Cycling Strategies.
What each one actually does
Pulsatile secretagogue stack
- Mechanism. Mod GRF is a stabilised GHRH analogue that asks the pituitary somatotropes to release stored GH. Ipamorelin is a GHRP that activates the ghrelin receptor on the same cells, deepening the same pulse. The architecture is what the body does naturally - just deeper and on a schedule that aligns with sleep.
- What you measure. IGF-1 climbs modestly - typical 6-week response on a clean stack is +50 to +150 ng/mL above baseline, depending on baseline IGF-1 and the dose. Stays in physiologic range for almost everyone.
- What you feel. Sleep deepens within the first week. Recovery between training sessions improves around week 4–6. Body-comp signal is real but modest - this stack is recovery infrastructure first.
- Ceiling. The pituitary can only release what it has stored. The stack pulses harder, but the total GH output is bounded by your endogenous capacity. For someone with normal pituitary function, that ceiling is enough to feel the difference. For someone with adult-onset GHD, it isn’t.
Recombinant somatropin (rHGH)
- Mechanism. Direct subcutaneous injection of recombinant human GH. Bypasses the pituitary entirely. The pharmacokinetics depend only on the injection - not on receptor sensitivity, not on stored pituitary inventory, not on fasting state.
- What you measure. IGF-1 climbs as much as the dose permits. At supraphysiologic doses (3+ IU/day in non-deficient adults) IGF-1 climbs into supraphysiologic ranges that you don’t reach with secretagogues at any dose.
- What you feel. Faster body-comp signal at matched timeline - visible recomposition at 8–12 weeks where secretagogues might need 6+ months. Recovery improvements at similar timeline. Side-effect signal also faster - carpal tunnel-like symptoms, water retention, glucose drift can show up in weeks rather than months.
- Ceiling. Effectively dose-limited by side-effect tolerance and bloodwork drift, not by physiology. The ceiling is where insulin sensitivity starts collapsing, not where the compound stops working.
The honest comparison
| Variable | Pulsatile stack (Mod GRF + Ipa) | Somatropin (rHGH) |
|---|---|---|
| IGF-1 ceiling | Physiologic (+50–150 ng/mL) | Supraphysiologic possible |
| Body-comp timeline | Modest, 6+ months | Visible, 8–12 weeks |
| Sleep / recovery | Strong, week 1–4 | Comparable, sometimes worse (higher RHR, water) |
| HbA1c drift risk | Modest, slow | Real, monitor every 8 weeks |
| Water retention / carpal tunnel | Rare, dose-dependent | Common at 3+ IU/day |
| Cost (typical) | ~$30–60 / month grey-market | ~$300–1500 / month at non-medical doses |
| Monitoring burden | Quarterly IGF-1 + HbA1c | Monthly IGF-1, 8-weekly HbA1c, lipids, watch BP and sleep apnea |
| Cycling discipline | 5-on / 2-off optional after week 8 | 4–8 month minimum runs; not a 4-week cycle compound |
| WADA category | S2 (banned at all times) | S2 (banned at all times) |
Where each actually fits
Secretagogue stack is the right call when:
- The goal is recovery, sleep, or modest body-comp.
- Pituitary function is intact (no GHD, no panhypopit history).
- Cost matters - secretagogues are an order of magnitude cheaper.
- Insulin sensitivity is already a watch-list item; the pulsatile architecture is gentler on it than continuous-elevation alternatives.
- The user wants “more of the natural axis” rather than “a different category of intervention.”
Somatropin is the right call when:
- The user has documented adult-onset GHD - replacement therapy is the indication, and TUE pathway exists for tested athletes.
- Aggressive body-comp goal with willingness to carry the monitoring burden.
- The user has already run a properly-dosed secretagogue stack for 8–12 weeks with sane bloodwork and genuinely plateaued - not after 4 weeks of haphazard dosing.
- The cost-to-monitoring ratio is favourable for the goal - rHGH at supraphysiologic doses is a category shift, not an increment.
MK-677 / Ibutamoren as the third option
Worth flagging since it shows up in the same conversation: MK-677 is an oral non-peptide ghrelin receptor agonist. Same downstream signal as a GHRP, but the kinetics are continuous (16+ hour half-life) rather than pulsed. Sits outside the pulsatile-vs-continuous-rhGH axis entirely - it’s “continuous secretagogue”: combines the receptor-desensitisation risk of any continuous compound with the pituitary-bound ceiling of a secretagogue. Convenient, but not the best of either world.
What stops people
- Treating somatropin as the natural escalation from secretagogues. The two compounds aren’t on a continuum - they’re different categories of intervention. Most users who want “more” from secretagogues should fix diet, training, and sleep first; somatropin is rarely the right answer for the next 5% of body-comp gain.
- Running rHGH with sloppy monitoring. The compound that demands the most monitoring discipline is the one most often run with the least. HbA1c every 8 weeks isn’t optional on rHGH at any dose past replacement.
- Underdosing rHGH and getting the worst of both worlds. rHGH at 1 IU/day in a non-deficient adult produces barely-physiological IGF-1 movement, near-zero body-comp signal, and the cost of the rHGH protocol. If the choice is sub-2-IU rHGH or a proper secretagogue stack, the secretagogue wins on cost-effectiveness every time.
- Counterfeit rHGH. Real rHGH is expensive and counterfeited heavily. The Beverly Hills International Anti-Aging Clinic 2 IU vial of unknown provenance might be saline. IGF-1 bloodwork at week 4 is the bare minimum to confirm the compound is doing anything; see Sourcing and Verification.
Decision frame
- Pituitary function intact, modest goal?
→ Mod GRF + Ipamorelin pre-bed. - Pituitary function intact, aggressive goal, AAS context,
willing to monitor?
→ Run the pulsatile stack alongside AAS first. If genuinely plateaued after 8–12 weeks, then somatropin enters the conversation. - Documented adult GHD, regardless of body-comp
interest?
→ Somatropin replacement via approved channel, with TUE if competing. - Tested athlete?
→ Both are S2. TUE possible for documented GHD with somatropin; not granted for “recovery” or “wellness” framing on either compound. See WADA Testing and Detection.
Cross-references
- GH Axis Playbook - full per-compound rundown across the GH axis.
- Cycling Strategies - the pulsatile-vs-continuous framing this article is downstream of.
- Pre-Bed GH-Secretagogue Protocol - the runbook for the pulsatile stack.
- Lean Mass and Hypertrophy application - somatropin protocol detail in the AAS-context block.
- Bloodwork for Peptide Users - the per-class panel and timing.